TRAW Stock — Traws Pharma Inc.: Cash, EV, Pipeline

Share price

$0.49

Market cap

$7.5M

Cash

$5.0M

Enterprise value

$2.5M

Balance sheet

Cash	$5.0M
Debt	$0.0M
Net cash	$5.0M
Enterprise value	$2.5M
Basic shares	15.3M shares
Fully diluted shares	55.7M shares
Fully diluted market cap	$27.3M
Cash per share	$0.33

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading TRAW daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Oct 13 - Nov 24	TRX-100	Phase 1	Healthy Volunteer	—
Dec 13, 2026 - Jan 24, 2027	TRX-100	Phase 2	Influenza	—
Jan 12 - Feb 23	TRX-100	Phase 2	Influenza	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Tivoxavir marboxil

Phase 1 · Active Modality: small molecule

Aliases TXM

Target cap-dependent endonuclease (CEN)

Indications

Bird flu (H5N1) and seasonal influenza (Phase 1)

Catalysts

— third quarter of 2026
— by the end of 2026

Status note Single-dose oral CEN inhibitor. Phase 1 completed in Australia; proposed Phase 2 dose-ranging and Phase 2a human challenge studies deferred. US IND on clinical hold (toxicology data package); UK MHRA challenge study deferred Jun 2026 pending toxicology resubmission. Acquired via Trawsfynydd merger Apr 2024.

Ratutrelvir

Phase 2 · Active Modality: small molecule

Aliases TRX01

Target SARS-CoV-2 main protease (3CL)

Indications

COVID-19 (Phase 2)

Status note Phase 1 completed Sep 2024 (Australia); Phase 2a completed. Intended for use without a CYP inhibitor such as ritonavir. Acquired via Trawsfynydd merger Apr 2024.

Narazaciclib

Phase 2 · Active Modality: small molecule

Aliases ON 123300

Target CDK4 (plus CDK, AMPK, ARK5, CSF1R)

Indications

Endometrial cancer (low-grade endometrioid, with letrozole) (Phase 2)
Advanced solid tumors / hematologic malignancies (Phase 1)

Status note Oral CDK4-plus multi-targeted kinase inhibitor. Phase 1/2a trial in endometrial cancer closed to accrual (database locked); monotherapy Phase 1 in advanced cancer closed. No further company-sponsored development; oncology assets limited to business development/out-licensing.

Rigosertib

Stage not disclosed · Active

Target PLK1

Indications

Epidermolysis bullosa-associated squamous cell carcinoma (Stage not disclosed)

Status note Legacy Onconova asset; studied only in investigator-initiated trials (IV or oral); limited to business development/out-licensing. Symbio license agreement mutually terminated Apr 17, 2025.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	TRX-100
Lead indication	Influenza
Lead phase	Phase 2
Active trials	4

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07503405	Phase 2	Not yet recruiting	Sponsor	TRAW	—	Influenza	—
NCT07371650	Phase 2	Active, not recruiting	Sponsor	TRAW	—	Influenza	—
NCT07157007	Phase 2	Recruiting	Sponsor	TRAW	—	COVID - 19	—
NCT07526506	Phase 1	Recruiting	Sponsor	TRAW	—	Healthy Volunteer	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Traws Pharma, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	1,203,260	+597,729	0.02%	2026-08-14
ADAR1 Capital Management	597,729	+443,631	0.02%	2026-08-14
Ikarian Capital	478,142	-200,000	0.07%	2026-08-14
Sphera Biotech	398,486	+398,486	0.05%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

TRAW — Traws Pharma Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders